Warning sign: toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries

Jabara, Refat; Ollerenshaw, Jeremy D.; Chronos, Nicolas; Tondato, Fernando; Conway, Damian; Molema, W.; Park, K; Mabin, Tom; King, Spencer B.; Robinson, Keith A.

doi:10.1016/j.carrev.2006.03.087

Cited by 12 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This makes the CoCr stent to have the same mechanical stability with thinner stent struts to result in less tissue coverage, greater stent flexibility in curved lesions, and a more filigree design [33]. Results of a porcine model over 4 weeks clearly showed that using the Co-Cr stent as a base for DES instead of the 316L stainless steel stent, the achieved anti-inflammatory effect of the drug-loaded stent is consistently more than for the 316L stainless steel [31,[34][35][36][37]. For this study, the average inflammation score was 0.45 AE 0.42 for D1, D2 and D3 groups, indicating only mild intimal inflammation in the segment implanted with all five groups.…”

Section: Discussionmentioning

confidence: 87%

In vitro and in vivo performance of a dual drug-eluting stent (DDES)

et al. 2010

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 87%

In vitro and in vivo performance of a dual drug-eluting stent (DDES)

et al. 2010

View full text Add to dashboard Cite

“…Therefore, the Co-Cr stent is able to maintain the same mechanical stability with much thinner stent struts, which results in greater stent flexibility in curved lesions, and a more filigree design 20 . Results of a porcine model over 4 weeks clearly showed that using the CoCr stent as a base for DES instead of the 316L stainless steel, the achieved anti-inflammatory effect of the drug-loaded stent is consistently more 3, 12, 13, 17, 43 . For this study, the mild intimal inflammation responses observed in both CES and BMS groups, an even in the pure polymer coated stent group, were due to the use of the Co-Cr stent.…”

Section: Discussionmentioning

confidence: 98%

In vivo Evaluation of Cenderitide-Eluting Stent (CES) II

Huang

Lim

et al. 2015

Ann Biomed Eng

View full text Add to dashboard Cite

The use of drug-eluting coronary stents has led to significant reduction in in-stent restenosis (ISR), but led to delayed endothelialization, necessitating the prolonged use of expensive anti-thrombotic drugs with their side-effects. Cenderitide (CD-NP) is a novel anti-proliferative chimeric peptide of semi-endothelial origin. Our previous work in vitro has demonstrated; that the smooth muscle cells (SMCs) were inhibited significantly more than endothelial cells (ECs) which is the desirable feature of an anti-restenosis drug. This work reports the effects of implantation of a centeritide-eluting stent (CES) on in-stent restenosis and endothelialization in an in vivo model. cenderitide-eluting stents were produced by coating bare metallic stents with CD-NP entrapped in biodegradable poly(ε-caprolactone) using an ultrasonic spray coater. A total of 32 stents were successfully implanted into 16 pigs, and all animal survived for 28 days. The plasma levels of CD-NP were significantly higher in the CES group than in the control group (bare metal stents and polymer coated stent) at post-stenting, indicating the successful release of CD-NP into blood stream in vivo. Furthermore, SEM analysis results showed the greater endothelial coverage of the stent struts, as well as between the struts in CES group. Moreover, histological results showed mild inflammation, and low fibrin score at 28 days. However, plasma cGMP (second messenger, cyclic 3′,5′ guanosine monophosphate) does not show a significant difference, and the CES is also unable to show significant difference in terms on neointimal area and stenosis, in comparison to BMS at 28 days.

show abstract

“…The long-term consequence of media necrosis in the pig model was evidenced in earlier study [29]. It has been demonstrated that loss of SMC could lead to late stent malapposition.…”

Section: In Vivo Studiesmentioning

confidence: 93%

“…Prior studies have examined novel polymer-free or absorbable polymer platforms for paclitaxel binding and delivery [29,31], but both these studies raised concerns with respect to paclitaxel toxicity. These findings not only reemphasized the narrow therapeutic window for eluted paclitaxel but also underscored the limited control of kinetic profiles and drug-loading capacity in the recent bioabsorbable-polymeric or non-polymeric approaches.…”

Section: In Vivo Studiesmentioning

confidence: 99%